Amazon Announces Five New Utility-Scale Solar Projects to Power Global Operations in China, Australia, and the U.S.
21.5.2020 10:00:00 EEST | Business Wire | Press release
Today, Amazon (NASDAQ: AMZN) announced five new renewable energy projects in China, Australia and the U.S. that further support Amazon’s commitment to reach 80% renewable energy by 2024 and 100% renewable energy by 2030 (and potentially as early as 2025), as well as to reach net zero carbon by 2040.
Amazon’s first renewable energy project in China is a 100 megawatt (MW) solar project in Shandong. Once complete, the project is expected to generate 128,000 megawatt hours (MWh) of clean energy annually.
Amazon’s second renewable energy project in Australia is a 105 MW solar project in New South Wales. This project will have the capacity to generate 250,000 MWh of clean energy each year, which is enough to power the equivalent of 40,000 average Australian homes.
Amazon’s newest renewable energy projects in the U.S. include two new projects in Ohio, a 200 MW solar project and an 80 MW solar project. Additionally, a new 130 MW solar project in Virginia brings the total number of renewable energy projects in the Commonwealth to 12. Once enabled, these three U.S.-based projects have the capacity to power the equivalent of 69,000 average U.S. homes each year.
When complete, the five new Amazon renewable energy projects totaling 615 MW of installed capacity will supply approximately 1.2 million MWh of additional renewable energy to the company’s fulfillment network and Amazon Web Services (AWS) data centers, which power Amazon and millions of customers globally.
To date, Amazon has announced 31 utility-scale wind and solar renewable energy projects and 60 solar rooftops on fulfillment centers and sort centers around the globe. Together, these projects totaling over 2,900 MW of capacity will deliver more than 7.6 million MWh of renewable energy annually, enough to power 680,000 U.S. homes.
“As a signatory to The Climate Pledge, we’re committed to meeting the goals of the Paris Agreement 10 years early and reaching net zero carbon across Amazon by 2040,” said Kara Hurst, Vice President of Sustainability, Amazon. “These five new renewable energy projects are a critical part of our roadmap to reach this goal. In fact, we believe it is possible to reach 100% renewable energy by 2025, five years ahead of the goals we announced last fall. While this will be challenging, we have a credible plan to get there.”
“Virginia’s energy future is bright. Through investments in clean energy we can reduce carbon emissions and create jobs to help drive long-term economic development,” said Virginia Senator Jennifer L. McClellan. “The announcement of this new Amazon solar project helps the Commonwealth meet our climate goals and contributes to our economic growth. The Virginia Clean Economy Act will help to drive more clean energy investments like this, to make Virginia a national hub for clean energy jobs.”
“Clean energy job creation is a crucial driver for long-term economic development in the Commonwealth,” said Virginia Delegate Richard C. Sullivan Jr. “I am pleased that Amazon continues to invest in Virginia’s clean energy future. The Virginia Clean Economy Act has put us on a path to 100 percent clean energy, and companies like Amazon are critical to helping us achieve that goal.”
Visit Amazon’s sustainability website for information and sustainability metrics that share the progress the company is making towards reaching The Climate Pledge. The goals, commitments, investments, and programs build on Amazon’s long-term commitment to sustainability through existing innovative programs, including Shipment Zero – Amazon’s vision to make all shipments net zero carbon, with 50% net zero carbon by 2030; sustainable packaging initiatives like Frustration-Free Packaging and Ship in Own Container, which have reduced packaging waste by 25% since 2015; renewable energy programs; investments in the circular economy with the Closed Loop Fund; and numerous other initiatives happening every day and led by teams across Amazon.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
About Amazon Web Services
For 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 76 Availability Zones (AZs) within 24 geographic regions, with announced plans for nine more Availability Zones and three more AWS Regions in Indonesia, Japan, and Spain. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005212/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom